Identification of Hub Genes Associated with Immune Cells in Dilated Cardiomyopathy via Weighted Gene Co-expression Network Analysis

Abstract Background: Dilated cardiomyopathy (DCM) is the most common cardiomyopathy which account for a majority of heart failure. Although massive clinic experiments and gene profiling analyses on DCM have been conducted, the molecular mechanism of DCM associated with immune cells has not been fully elucidated. This study was designed to discover the immune mechanism of DCM using integrative bioinformatics analysis and provide new insights into the pathophysiology of DCM. Methods: The GSE29819 dataset was downloaded, and Cibersort was applied to estimate the relative expression of 22 kinds of immune cells based on 14 samples of 7 DCM patients. Weighted gene co-expression network analysis (WGCNA) was performed to cluster the 2500 genes with the highest average expression into different modules and explore relationships between modules and immune cell types. Functional enrichment analysis was performed on key genes in significant modules identified by WGCNA and Cibersort. Key genes were then applied to Cytoscape to construct protein-protein interaction (PPI) network. Differentially expressed genes (DEGs) were identified based on DCM and normal controls in GSE29819 through R language. Hub genes were selected based on the DEGs and the genes identified by PPI and then verified via public GEO databases. Results: The yellow and tan modules with 163 genes were identified as the key modules based on top 2500 DCM microarrays, significantly correlated with M1 and M2 macrophages. The intersection of newly screened 17 genes based on 163 key genes through Cytoscape and 2682 DEGs were defined as hub genes including CCT2, CCL2, and TXN. The results were finally verified via GSE116250 datasets.Conclusions: The three hub genes associated with two immune cells identified by comprehensive bioinformatics analysis may play crucial roles in the pathophysiological mechanism of DCM, which provided potential immunological therapeutic targets and new insights into the treatment of DCM.